Role of the Perfluorocarbon Fluosal-DA in Coronary Angioplasty

Kerins, David M.

doi:10.1097/00000441-199403000-00009

Cited by 48 publications

(24 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Therefore, they are effi cient solvents, and their oxygencarrying capacity is relevant in patients receiving high concentrations of supplemental oxygen [ 43 , 44 ]. The only product based on perfl uorocarbon ever approved by the Food and Drug Administration (FDA) was Fluosol ® in 1989, for perfusion during percutaneous coronary angioplasty [ 45 ]. In 1994 the product has been withdrawn from the market due to its insuffi cient applicability in clinical practice.…”

Section: Perfluorocarbon-based Oxygen Carriersmentioning

confidence: 99%

Diaspirin Cross-Linked Hemoglobin and Blood Substitutes

Romagnoli

Zagli

Ricci

2015

Reducing Mortality in Critically Ill Patients

View full text Add to dashboard Cite

Oxygen delivery (DO 2 ) to organs and tissues depends on fl ow generated by the heart (cardiac output, CO) and arterial oxygen content. Arterial oxygen content depends on oxygen partial pressure (PaO 2 ) and hemoglobin (Hb) concentration and saturation. In case of hypoxemia and/or low CO states, Hb concentration may play a key role in preventing tissue hypoxia and cellular dysfunction.Although Hb concentration in perioperative settings and in critical care is a crucial aspect for almost all patients, the optimal values are still a matter of debate [ 1 ]. Nonetheless, current guidelines and recommendations suggest lower "transfusion triggers" than in the past, encouraging blood-saving techniques following a multidisciplinary, multi-procedural approach [ 2 ]. The diffi culties of supplying red blood cells (RBCs), the need to overcome problems of storage and transfusion (refrigeration and crossmatching), the aim to avoid potential transfusions' harming effects (infection, transfusion reactions, transfusion-related acute lung injury, immunomodulation) [ 3 , 4 ], and the need for alternatives to biological blood for religious reasons (e.g., Jehovah's Witnesses) [ 5 , 6 ] have led scientists and companies, over the past three decades, to synthesize and test artifi cial blood solutions. Oxygen carrier (OC) is a generic defi nition for blood substitutes, blood surrogates, artifi cial Hb, or artifi cial blood. These substances mimic oxygen-carrying function of the RBCs (Table 11.1 ) and are characterized by a long shelf life. In other words, OCs are pharmacological substances that aim to improve DO 2 independently from RBCs.

show abstract

Section: Perfluorocarbon-based Oxygen Carriersmentioning

confidence: 99%

Diaspirin Cross-Linked Hemoglobin and Blood Substitutes

Romagnoli

Zagli

Ricci

2015

Reducing Mortality in Critically Ill Patients

View full text Add to dashboard Cite

show abstract

“…115 O Fluosol DA 20%® (Green Cross Corp., Japão), licenciado para uso clínico em 1989 em angioplastia percutânea transluminal para oxigenar o leito vascular distal, chegou a ser liberado no Japão para uso clínico. [116][117][118][119] Foi retirado do mercado em 1994 por baixas vendas e reações adversas.…”

Section: Perfluorcarbonos (Pfcs)unclassified

Importância dos carreadores de oxigênio livre de células

Novaretti¹

2007

Rev. Bras. Hematol. Hemoter.

View full text Add to dashboard Cite

IntroduçãoNo mundo todo, a necessidade de transfusões sangüíneas vem crescendo progressivamente. No Brasil, enquanto a demanda de sangue cresce à taxa de 1% ao ano, as expectativas de crescimento das doações de sangue variam de 0,5 a 0,7%/ano. 1 Conseqüentemente, a estimativa para o ano de 2030 é de um déficit de aproximadamente um milhão de unidades de sangue coletado, levando-se em conta o crescimento populacional projetado e as necessidades crescentes de transfusão, em especial para os que a necessitam cronicamente, para cirurgias de grande complexidade e no atendimento às emergências.2 Deve-se ressaltar que essa projeção não inclui situações de calamidade pública e desastres naturais.Se estimarmos as necessidades internacionais de transfusão de sangue e componentes, tendo por base a estimativa de 0,05 unidades per capita por ano, pode ser projetada uma demanda de assustadoras 300 milhões de unidades de sangue por ano.3 Quando são computados os números disponí-veis de transfusões de sangue em termos mundiais, temos cerca de 90 milhões de unidades transfundidas por ano. Caso esse número seja verdadeiro, há falta de 200 milhões de bolsas de sangue/ano. 4 Obviamente essas estimativas estão sujeitas a críticas, mas é evidente que não há suprimento total de sangue, particularmente de alguns tipos (como os Rhnegativo) em situações emergenciais, e a sazonalidade é importante fator que compromete o fornecimento de sangue. Deve-se ressaltar que, apesar de os progressos para o aumento da segurança transfusional e da diminuição vertigi-

show abstract

“…Therefore, its use as a blood substitute has been abandoned. However, in 1989 it was approved by the American Food and Drug Administration (FDA) for use during percutaneous transluminal coronary angioplasty (PTCA) for the prevention and treatment of distal myocardial ischemia [3]. In a large clinical trial 430 patients were treated with Fluosol-DA to reduce reperfusion injury following myocardial infarction.…”

Section: Clinical Use Of Artificial Oxygen Carriersmentioning

confidence: 99%

Biomedical Applications of Artificial Oxygen Carriers

Waschke¹,

Lenz²

1999

Transfus Med Hemother

View full text Add to dashboard Cite

At present, the rapid progress in science and technology around artificial oxygen carriers has advanced to a critical stage.Therefore, it can be assumed that these substances will be clinically available as substitutes for red blood cells within the next years. It can be expected that the major impact of hemoglobin- and perfluorocarbon-based oxygen carriers will be on the use as intermittent blood substitutes during or anticipating acute blood loss from surgery or trauma. However, further applications for artificial oxygen carriers are emerging which cannot fullfilled by red blood cells. Clinical studies are testing now the therapeutic abilities of artificial oxygen carriers in renal anemia, transplantation medicine, cancer therapy, sickle cell disease, treatment of septic shock, treatment of stroke, reduction of air embolism during cardiopulmonary bypass, and as an adjunct to respiratory therapy (‘liquid ventilation’) . In addition, use of artificial oxygen carriers in animal experiments aims at the improvement of oxygen supply in the microcirculation of organs suffering from ischemia. For the long term, biological engineering may increase desired pharmacologic properties of artificial oxygen carriers and widen their spectrum of indications.

show abstract

Role of the Perfluorocarbon Fluosal-DA in Coronary Angioplasty

Cited by 48 publications

References 21 publications

Diaspirin Cross-Linked Hemoglobin and Blood Substitutes

Diaspirin Cross-Linked Hemoglobin and Blood Substitutes

Importância dos carreadores de oxigênio livre de células

Biomedical Applications of Artificial Oxygen Carriers

Contact Info

Product

Resources

About